Ann: $6.6 million Placement to advance clinical trial pipeline, page-17

Yep, anyone who was contacted prior as sophs were obviously being contacted could of got out when the share price was trading 0.008 on the back of the ADVENT-AML Phase 1B update, with the knowledge they could get back in at a 50% discount. Seemingly thats what happened with 184 million traded on the news.

What would have been better was let the share price run off the back of the news without contacting leadbrokers, that way the market would rate the company fairly with no insiders knowing a 50% discount and huge dilution was coming. Might have been able to get up to 1cent or more, then at this point after a couple of weeks offer a discount of only 20% or so at a more fair valuation, without the incredible dilution.

As always the free attaching options are not helping. Anyone who participated, can just dump their shares at 0.004 or above if they are lucky, and then the options are a totally free shot at upside with no risk. Terrible management of this CR, but not a surprise coming from this management, its almost comical at this point.